B-218 Role of Delta Tocotrienol and Resveratrol Supplementation in Regulation of Micro RNAs in Patients With Metabolic Syndrome: A Randomized Controlled Trial

Abstract

Abstract Background Micro-RNAs (miRNAs) are involve in the regulation of central obesity, insulin resistance, inflammation and dyslipidemia in development of MetS. δ-tocotrienol and resveratrol improve the insulin resistance, inflammation and clinico-biochemical parameters in the patients with MetS. Objective To determine the effect of δ-tocotrienol and Resveratrol Mixture (TRM) supplementation for 24 weeks in comparison with placebo, on the relative expression of metabolic related miR-130b, miR-221, miR-15b-, miRNA-122, and miR-376b in the patients with MetS. Methods This randomized placebo-controlled trial was conducted at AFIP, NUMS, Pakistan. A total of 82 adult MetS patients, aged 18 to 60 years of both genders, were enrolled and randomly grouped into TRM (n = 41) and Placebo (n = 41). The TRM group was given 400 mg capsules of (δ-tocotrienol 250 mg; Resveratrol 150 mg), and placebo received 400 mg cellulose capsules twice daily for 24 weeks. miRNA was extracted by Trizole L S reagent with cel-miR-39 (Spike-In control). The cDNA was prepared by Reverse Transcriptase Kit. miRNAs expression profile was done by using qRT-PCR Kit (Qiagen) protocol on the Rotor-Gene. Results The TRM supplementation significantly (P < 0.001) upregulated miR-130b-5p (3.05fold), miR-221-5p (2.45fold), and downregulated miR-122-5p by 2.22fold as compared to placebo after 24 weeks. No significant difference was observed in miR-15b-5p and miR-376b-5p. Furthermore, patients in the TRM group had significant (P < 0.05) correlation in improvement of MetS biomarkers and miRNAs including hs-CRP, miR-130b; miR-221, TNF-α; miR-221, fasting plasma glucose, miR-122, triglyceride and miR-130b with waist circumference. No significant side effect was reported. Conclusion TRM daily supplementation in addition to dietary restriction, is effective in the improvement of the metabolic syndrome components by upregulation of miR-130b-5p involve in central obesity, inflammation; miR-221-5p by decreasing insulin resistance and downregulation of miRNA 122 to improve dyslipidemia in the patients with MetS.